General guidelines for diagnosis and treatment

General guidelines for diagnosis and treatment of colorectal cancer
Attention should be paid to the role of the multidisciplinary team (MDT) in the diagnosis and treatment of colorectal cancer. It is recommended that designated senior attending physicians from colorectal surgery, hepatobiliary surgery, oncology, radiology, imaging, and other relevant departments participate in the MDT, and that the MDT meeting be held at a fixed time and venue. MDT is particularly recommended for patients with liver-limited metastases, late-stage patients with potentially resectable metastases, and patients with middle and low rectal cancers.
Diagnostic principles for colorectal cancer
Colorectal cancer screening of asymptomatic healthy population
Colorectal screening annually is recommended for highrisk population. The average-risk subjects at the age of 50 to 74 years should also accept colorectal cancer screening (1) (2) . The screening includes a risk accessment by questionnaire and fecal immunochemical occult blood test (FIT). The subjects tested positive in FIT or risk accessment should undergo colonoscopy examination (3) (4) (5) (6) (7) (8) .
If neoplastic lesions were found under colonoscopy, biopsy and histological examination are required. All polyps and flat neoplatic lesions should be removed. If no lesion was found under colonoscopy, repeated colonoscopy is recommended in 5 years. If advanced colorectal adenoma (adenoma with diameter ≥1 cm, with villious differentiation, or with high-grade dysplasia) were diagnosed, the patient should undergo colonoscopy once every 1−3 years. The interval of follow-up colonoscopy could be extended to 3−5 years if there is no recurrent adenoma in the last colonoscopy. Recommendations of colorectal cancer screening for subjects with family history of colorectal cancer please refer to Section 5 of this guideline. Patients with inflammatory bowel disease should discuss with specialist physician to determine follow-up colonoscopy interval. 
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rectal cancer: a systematic review and meta-analysis. Dig Surg 2014;31:123-34. be treated by endoscopic removal ( Table 3) . After resection, postoperative pathology is used to determine the subsequent treatment regimen ( ESD Operation -EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection. a , It is recommended that pathological testing of all non-pedunculated polyps or polyps that are suspected to be cancerous be conducted before determining whether endoscopic removal should be performed. b , The risk of cancer accompanied by regional lymph node metastases at the T1 stage is approximately 15%. Local endoscopic excision cannot determine the status of lymph nodes. After endoscopic removal of T1 (SM) cancers, not only should local colonoscopy examination be carried out, but testing of the tumor marker, carcinoembryonic antigen (CEA), abdominal ultrasound, and abdominal CT should also be conducted simultaneously (1). c , The histological criteria for confirming curative endoscopic resection of T1 colorectal cancer tissues are as follows: 1) Lesions with submucosal invasion <1 mm; 2) Absence of lymphovascular invasion; 3) Well-differentiated tumors; 4) Absence of tumor budding; and 5) Distance of tumor from resection margin ≥1 mm (2,3). d , When it is impossible to determine whether resection margins are negative or positive, it is recommended that follow-up endoscopy be performed in 3−6 months. If resection margins are negative, follow-up can be conducted within 1 year after endoscopic treatment (4, 5) . e , Larger lesions may require piecemeal endoscopic mucosal resection (PEMR). However, the local recurrence rate is high with PEMR and requires increased monitoring (6). . c , The patient should be informed that the probability of poor outcomes will significantly increase with sessile malignant polyps, including disease recurrence, mortality, and blood dissemination, which is highly associated with positive resection margin after endoscopic resection (10). 12. 
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Treatment of unresectable colon cancer
Radical resection cannot be achieved in some T4b, M0 patients even after combined organ resection. In these patients, 5-FU-based mono-chemotherapy or combination chemotherapy with oxaliplatin or irinotecan, or even triple drug chemotherapy can be used according to the patient's condition (1) . Clinical trials on advanced colorectal cancer have also shown that chemotherapy can be combined with bevacizumab or cetuximab (2-5). For some T4b patients with local invasion of the sigmoid colon, local radiotherapy can also be performed to increase the response rate of treatment and increase the probability of conversion (6) . Endoscopic stent implantation (7,8) or bypass surgery can be carried out to remove obstruction in T4b colon cancer patients with intestinal obstruction.
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To reduce drug-induced liver injury, the course of neoadjuvant chemotherapy is usually limited to 2−3 months.
Local management methods for metastatic lesions not only include surgery but also radiofrequency ablation, microwave ablation, and stereotactic radiation therapy.
The CRS contains five parameters: lymph node positivity for primary tumor, synchronous metastases or metachronous metastases that are <12 months from the date of resection of the primary lesion, >1 liver metastases, preoperative carcinoembryonic antigen (CEA) levels >200 ng/mL, and maximum diameter of metastasis >5 cm. Each item scores 1 point. A score of 0−2 points is low while a score of 3−5 points is high. The higher the CRS score, the greater the risk of postoperative recurrence, and the more beneficial the perioperative chemotherapy (1,2).
Treatment of initially unresectable metastatic colon cancer
Treatment for initially unresectable metastatic colon cancer can be divided into conversion therapy and palliative treatment based on the resectability of the metastatic lesions. As primary lesions present with symptoms of obstruction, bleeding, and perforation, the primary lesion should be treated first. Comprehensive management and treatment should be used under the guidance of the MDT for these patients.
Patients with potentially resectable tumors should undergo conversion chemotherapy first to shrink metastatic lesions, after that the resectability of these lesions should be re-assessed. Table 7 shows the conversion chemotherapy regimens.
Palliative therapy mainly consists of systemic therapy. Table 8 shows first-line regimens for palliative therapy.
First-line regimens for palliative therapy
Second-line regimens for palliative therapy
In principle, the regimen of second-line treatment should be changed. The original chemotherapy regimen can be used for stop-and-go patients. Targeted therapy drugs can be used in second-line treatment if they are not used in first-line treatment. If first-line chemotherapy is combined with bevacizumab, the chemotherapy regimen can be changed in second-line treatment while retaining bevacizumab (7). If first-line chemotherapy is combined with cetuximab for palliative treatment, cetuximab is not recommended to be used continuously in second-line therapy. The modified XELIRI (irinotecan + capecitabine regimen, mXELIRI) can be used for second-line chemotherapy (8) .
Third-line regimens for palliative therapy
For patients with both wild-type RAS and BRAF genes, cetuximab ± irinotecan (for patients who are cetuximabnaive) regorafenib, or clinical trials are recommended. For patients with RAS or BRAF mutations, regorafenib or clinical trials are recommended. 
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Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metasticic colorectal cancer. JAMA Oncol 2016. c , If the patient has a responsible or stable disease after 4−6 months of first-line treatment, maintenance therapy can be used or systemic therapy can be temporarily suspended. 5-FU/LV or capecitabine monotherapy ± bevacizumab is recommended for maintenance therapy due to low toxicity (4, 5) . The use of cetuximab in maintenance therapy has been poorly studied. d , Recently, many retrospective studies have shown that the prognosis of metastatic colon cancer with right-sided primary lesions (ileocecal junction to splenic flexure) is worse than that of left-sided primary lesions (splenic flexure to the rectum). Retrospective subgroup analysis data of randomized, controlled trials showed that the objective response rate and overall survival of cetuximab are both better than that of bevacizumab for patients with left-sided colorectal cancer. For patients with right-sided colon cancer, cetuximab shows minor advantages over bevacizumab in objective response rate but overall survival is worse than that of bevacizumab (6). a , Recently, many retrospective studies have shown that the prognosis of metastatic colon cancer with right-sided primary lesions (ileocecal junction to splenic flexure) is worse than that of left-sided primary lesions (splenic flexure to the rectum). Retrospective subgroup analysis data of randomized, controlled trials showed that the objective response rate and overall survival of cetuximab are both better than that of bevacizumab for patients with left-sided colorectal cancer. For patients with right-sided colon cancer, cetuximab shows minor advantages over bevacizumab in objective response rate but overall survival is worse than that of bevacizumab (1). b , Capecitabine combined with cetuximab is not recommended. 
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Treatment of postoperative recurrence in metastatic colon cancer
5-FU
FOLFIRI + bevacizumab
Colon cancer follow-up
Postoperative follow-up for stage I patients: once every 6 months for 5 years. Postoperative follow-up for stage II/III patients: once every 3 months for 3 years, followed by once every 6 months to 5 years, and then once a year. The follow-up should include: 1) Physical examination with an emphasis on digital rectal examination; 2) Blood CEA levels; 3) Liver ultrasonography for stage I/II patients; 4) Chest, abdominal, and pelvic CT once a year for stage III patients or when there are CEA or ultrasound abnormalities; and 5) Colonoscopy examination within 1 year after surgery. If full colonoscopy was not carried out before surgery due to tumor obstruction, examinations should be carried out in 3−6 months after surgery. If no abnormalities are found, follow-up examinations should be carried within 3 years, followed by once every 5 years (1). Follow-up frequency for R0 resection/ablation for stage IV patients with metastases: once every 3 months for 3 years, followed by once every 6 months until Year 5, and then once a year. Follow-up should include: physical examination; blood CEA levels; and enhanced chest, abdominal, and pelvic CT once every 6−12 months. If the patient's physical status does not allow him/her to receive anti-neoplastic treatment due to recurrence, it is not advisable to conduct routine tumor follow-up/monitoring for the patient. PET/CT is only recommended for clinically suspected recurrence while routine imaging is negative, such as persistently elevated CEA. PET examination is not recommended as a routine follow-up/ monitoring method.
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Treatment principles for rectal cancer
Treatment principles for non-metastatic rectal cancer
Treatment principles for rectal adenoma
Refer to Section 3.1.1.1 Endoscopic treatment for treatment of rectal adenomas. Usually different treatment recommendations are given based on the distance between the lesion and the anal verge in high-grade rectal neoplasia. For patients with a distance of ≤8 cm between the lesion and anal verge, it is primarily recommended that transanal local excision or endoscopic resection be performed, followed by transanal endoscopic microsurgery (TEM), laparoscopic or open rectal resection. For patients with a distance of 8−15 cm, endoscopic resection is the treatment of first choice, followed by TEM, laparoscopic, or open rectal resection.
Treatment principles for cT1−2N0 rectal cancer
The treatment principles for cT1−2N0 rectal cancer is radical surgery. Transanal local excision can be considered in cT1N0 patients when it is difficult to perform sphincterpreserving surgery. Radical surgery should be considered if the following pathological situation occur after local excision: poorly differentiated tumors, vascular invasion, positive resection margin, sm3, or T2. Radiotherapy/ chemotherapy is recommended for patients who do not undergo radical surgery (1, 2) . Concurrent chemoradation can be considered if it is difficult to carry out organ preservation. operation in cT2N0 patients but the patient has a strong intention for organ preservation. The next treatment can be selected according to the extent of tumor response: 1) Watch & wait for patients who have complete clinical response (cCR); 2) Transanal local excision for patients with ycT1 tumors; and 3) Radical rectal cancer surgery for patients with ycT2 tumors. The current international consensus for complete clinical remission (cCR) (3) includes: 1) Digital rectal examination: normal; 2) White and flat mucosal scars under the endoscope, accompanied by peripheral capillary telangiectasia, without signs of malignant ulcers or nodulesd; and 3) High resolution MRI in T2 shows completely dark, without moderate intensity signals and lymph nodes; in DW phase, no tumor signal for B800-B1000 and/or, in ADC shows little or no signal, and intestinal wall linear signals in the tumor area. The watch and wait strategy is currently under exploration. There is a need to fully communicate with the patients, with an emphasis for more frequent follow-up and let them know the results of salvage therapy after tumor recurrence. It is recommended that follow-up visits should be carried out every 1−2 months within 2 years. The assessment methods mainly consist of digital rectal examination, endoluminal ultrasound, and functional MR. There is still controversy over the use of biopsy in the scar region of the primary lesion. 
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Treatment principles
Rectal cancer follow-up
Refer to Section 3.3 Colon cancer follow-up.
Principles of screening for hereditary colorectal cancer and genetic testing
Management strategy after genetic screening is shown in Table 11 . All colorectal cancer patients should be asked on their family history of cancer and their intestinal polyp status should be determined. Specific disease screening should be carried out for patients who fulfilled the following criteria in regional medical center: 1) Familial adenomatous polyposis (FAP) screening (including colonoscopy examination and FAP genetic screening) is required for individuals with ≥20 polyps in the entire colon and rectum or with a confirmed FAP family member (1); 2) Peutz-Jeghers syndrome (PJ) screening is required for individuals with significant melanosis in the oral mucosa, lips, nose, cheeks, periorbital area, reproductive organs, hands and feet, perianal skin, etc. Patients with confirmed PJ family members also should receive screening. STK11 gene mutation test is recommended (2); and 3) Patients excluding FAP and PJ syndrome should receive screening for Lynch syndrome. Individuals who fulfilled the following criteria should be suspected of Lynch syndrome family and detected the relevant genes (mismatch repair genes MLH1, MSH2, MSH6, and PMS2) (3, 4) . There are at least two histopathologically diagnosed colorectal cancer patients in the family, and 2 cases of them are first-degree relatives (parents and offspring, or siblings), and meet any one of the following criteria: 1) At least one case with multiple colorectal cancer (including adenomas); 2) At least one with onset of colorectal cancer <50 years; and 3) At least one with Lynch syndrome associated-extracolonic cancers (including gastric cancer, endometrial cancer, small intestine cancer, ureter and renal pelvis cancer, ovarian cancer, and hepatobiliary cancers) (5). After genetic testing, protocols in the following table are used for management and follow-up for those with confirmed pathological germline mutations and mutation carriers. General population screening can be carried out for individuals who are not mutation carriers. For those in which germline mutations cannot be determined, follow-up strategy should be discussed and decided by the doctor and individiuals according to family history and clinical presentations.
